{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:37:48Z","timestamp":1775885868400,"version":"3.50.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870255"],"award-info":[{"award-number":["81870255"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY21H020001"],"award-info":[{"award-number":["LY21H020001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2021KY306"],"award-info":[{"award-number":["2021KY306"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005315","name":"Natural Science Foundation of Ningbo Municipality","doi-asserted-by":"publisher","award":["2021J296"],"award-info":[{"award-number":["2021J296"]}],"id":[{"id":"10.13039\/501100005315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005315","name":"Natural Science Foundation of Ningbo Municipality","doi-asserted-by":"publisher","award":["2019A610343"],"award-info":[{"award-number":["2019A610343"]}],"id":[{"id":"10.13039\/501100005315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. of Cardiovasc. Trans. Res."],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12265-022-10298-x","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T14:05:12Z","timestamp":1660745112000},"page":"209-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Advantages, Challenges, and Future of Human-Induced Pluripotent Stem Cell Lines in Type 2 Long QT Syndrome"],"prefix":"10.1007","volume":"16","author":[{"given":"Dihui","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zequn","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lichao","family":"Cen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiachun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongfei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3573-8051","authenticated-orcid":false,"given":"Jiangfang","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"issue":"2","key":"10298_CR1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jacc.2006.10.010","volume":"49","author":"DJ Tester","year":"2007","unstructured":"Tester DJ, Ackerman MJ. Postmortem long QT syndrome genetic testing for sudden unexplained death in the young. J Am Coll Cardiol. 2007;49(2):240\u20136.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10298_CR2","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1161\/CIRCULATIONAHA.109.863209","volume":"120","author":"PJ Schwartz","year":"2009","unstructured":"Schwartz PJ, et al. Prevalence of the congenital long-QT syndrome. Circulation. 2009;120(18):1761\u20137.","journal-title":"Circulation"},{"issue":"1","key":"10298_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng0196-17","volume":"12","author":"Q Wang","year":"1996","unstructured":"Wang Q, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996;12(1):17\u201323.","journal-title":"Nat Genet"},{"issue":"5","key":"10298_CR4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/0092-8674(95)90358-5","volume":"80","author":"ME Curran","year":"1995","unstructured":"Curran ME, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80(5):795\u2013803.","journal-title":"Cell"},{"issue":"5","key":"10298_CR5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/0092-8674(95)90359-3","volume":"80","author":"Q Wang","year":"1995","unstructured":"Wang Q, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80(5):805\u201311.","journal-title":"Cell"},{"issue":"23","key":"10298_CR6","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.jacc.2009.12.063","volume":"55","author":"N Hofman","year":"2010","unstructured":"Hofman N, et al. Active cascade screening in primary inherited arrhythmia syndromes: does it lead to prophylactic treatment? J Am Coll Cardiol. 2010;55(23):2570\u20136.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10298_CR7","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1161\/CIRCEP.111.962019","volume":"5","author":"PJ Schwartz","year":"2012","unstructured":"Schwartz PJ, Crotti L, Insolia R. Long-QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol. 2012;5(4):868\u201377.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"12","key":"10298_CR8","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1161\/CIRCRESAHA.116.304494","volume":"116","author":"K Sallam","year":"2015","unstructured":"Sallam K, et al. Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes. Circ Res. 2015;116(12):1989\u20132004.","journal-title":"Circ Res"},{"issue":"3","key":"10298_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10557-017-6735-0","volume":"31","author":"S Casini","year":"2017","unstructured":"Casini S, Verkerk AO, Remme CA. Human iPSC-derived cardiomyocytes for investigation of disease mechanisms and therapeutic strategies in inherited arrhythmia syndromes: strengths and limitations. Cardiovasc Drugs Ther. 2017;31(3):325\u201344.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"44","key":"10298_CR10","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehy508","volume":"39","author":"PJ Schwartz","year":"2018","unstructured":"Schwartz PJ, Crotti L, George AL Jr. Modifier genes for sudden cardiac death. Eur Heart J. 2018;39(44):3925\u201331.","journal-title":"Eur Heart J"},{"issue":"1","key":"10298_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2012.08.005","volume":"161","author":"JR Giudicessi","year":"2013","unstructured":"Giudicessi JR, Ackerman MJ. Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes. Transl Res. 2013;161(1):1\u201314.","journal-title":"Transl Res"},{"issue":"4","key":"10298_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663\u201376.","journal-title":"Cell"},{"issue":"5","key":"10298_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861\u201372.","journal-title":"Cell"},{"issue":"7337","key":"10298_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nature09747","volume":"471","author":"I Itzhaki","year":"2011","unstructured":"Itzhaki I, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature. 2011;471(7337):225\u20139.","journal-title":"Nature"},{"issue":"8","key":"10298_CR15","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/eurheartj\/ehr073","volume":"32","author":"E Matsa","year":"2011","unstructured":"Matsa E, et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J. 2011;32(8):952\u201362.","journal-title":"Eur Heart J"},{"issue":"2","key":"10298_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1242\/dmm.008409","volume":"5","author":"AL Lahti","year":"2012","unstructured":"Lahti AL, et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech. 2012;5(2):220\u201330.","journal-title":"Dis Model Mech"},{"issue":"24","key":"10298_CR17","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1038\/emboj.2013.240","volume":"32","author":"M Bellin","year":"2013","unstructured":"Bellin M, et al. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. Embo j. 2013;32(24):3161\u201375.","journal-title":"Embo j"},{"issue":"4","key":"10298_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.14573\/altex.1805301","volume":"35","author":"FA Grimm","year":"2018","unstructured":"Grimm FA, et al. A human population-based organotypic in vitro model for cardiotoxicity screening. Altex. 2018;35(4):441\u201352.","journal-title":"Altex"},{"issue":"1","key":"10298_CR19","doi-asserted-by":"publisher","first-page":"e000043","DOI":"10.1161\/HCG.0000000000000043","volume":"11","author":"K Musunuru","year":"2018","unstructured":"Musunuru K, et al. Induced pluripotent stem cells for cardiovascular disease modeling and precision medicine: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2018;11(1):e000043.","journal-title":"Circ Genom Precis Med"},{"issue":"11","key":"10298_CR20","doi-asserted-by":"publisher","first-page":"e002345","DOI":"10.1161\/CIRCGEN.118.002345","volume":"11","author":"CG Vanoye","year":"2018","unstructured":"Vanoye CG, et al. High-throughput functional evaluation of KCNQ1 decrypts variants of unknown significance. Circ Genom Precis Med. 2018;11(11):e002345.","journal-title":"Circ Genom Precis Med"},{"issue":"2","key":"10298_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0092-8674(00)80728-X","volume":"97","author":"GW Abbott","year":"1999","unstructured":"Abbott GW, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 1999;97(2):175\u201387.","journal-title":"Cell"},{"issue":"5","key":"10298_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.joa.2015.11.009","volume":"32","author":"JL Smith","year":"2016","unstructured":"Smith JL, et al. Molecular pathogenesis of long QT syndrome type 2. J Arrhythm. 2016;32(5):373\u201380.","journal-title":"J Arrhythm"},{"issue":"17","key":"10298_CR23","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1161\/CIRCULATIONAHA.105.572453","volume":"112","author":"PA Brink","year":"2005","unstructured":"Brink PA, et al. Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. Circulation. 2005;112(17):2602\u201310.","journal-title":"Circulation"},{"issue":"21","key":"10298_CR24","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1161\/CIRCULATIONAHA.107.726950","volume":"116","author":"L Crotti","year":"2007","unstructured":"Crotti L, et al. The common long-QT syndrome mutation KCNQ1\/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation. 2007;116(21):2366\u201375.","journal-title":"Circulation"},{"issue":"6","key":"10298_CR25","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1161\/CIRCGENETICS.108.825547","volume":"2","author":"A Winbo","year":"2009","unstructured":"Winbo A, et al. Low incidence of sudden cardiac death in a Swedish Y111C type 1 long-QT syndrome population. Circ Cardiovasc Genet. 2009;2(6):558\u201364.","journal-title":"Circ Cardiovasc Genet"},{"issue":"3","key":"10298_CR26","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/cvr\/cvaa019","volume":"117","author":"YK Lee","year":"2021","unstructured":"Lee YK, et al. MTMR4 SNVs modulate ion channel degradation and clinical severity in congenital long QT syndrome: insights in the mechanism of action of protective modifier genes. Cardiovasc Res. 2021;117(3):767\u201379.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10298_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0008-6363(99)00195-9","volume":"44","author":"T Nakajima","year":"1999","unstructured":"Nakajima T, et al. Voltage-shift of the current activation in HERG S4 mutation (R534C) in LQT2. Cardiovasc Res. 1999;44(2):283\u201393.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10298_CR28","doi-asserted-by":"publisher","first-page":"19203","DOI":"10.1038\/s41598-019-55837-w","volume":"9","author":"FCP Mesquita","year":"2019","unstructured":"Mesquita FCP, et al. R534C mutation in hERG causes a trafficking defect in iPSC-derived cardiomyocytes from patients with type 2 long QT syndrome. Sci Rep. 2019;9(1):19203.","journal-title":"Sci Rep"},{"issue":"11","key":"10298_CR29","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.hrthm.2019.04.031","volume":"16","author":"NV Chavali","year":"2019","unstructured":"Chavali NV, et al. Patient-independent human induced pluripotent stem cell model: A new tool for rapid determination of genetic variant pathogenicity in long QT syndrome. Heart Rhythm. 2019;16(11):1686\u201395.","journal-title":"Heart Rhythm"},{"issue":"7313","key":"10298_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature09342","volume":"467","author":"K Kim","year":"2010","unstructured":"Kim K, et al. Epigenetic memory in induced pluripotent stem cells. Nature. 2010;467(7313):285\u201390.","journal-title":"Nature"},{"key":"10298_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ijcard.2017.04.038","volume":"240","author":"M Mura","year":"2017","unstructured":"Mura M, et al. The KCNH2-IVS9-28A\/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2. Int J Cardiol. 2017;240:367\u201371.","journal-title":"Int J Cardiol"},{"issue":"1","key":"10298_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jacc.2018.04.041","volume":"72","author":"P Garg","year":"2018","unstructured":"Garg P, et al. Genome editing of induced pluripotent stem cells to decipher cardiac channelopathy variant. J Am Coll Cardiol. 2018;72(1):62\u201375.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10298_CR33","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1172\/JCI94996","volume":"128","author":"S Chai","year":"2018","unstructured":"Chai S, et al. Physiological genomics identifies genetic modifiers of long QT syndrome type 2 severity. J Clin Invest. 2018;128(3):1043\u201356.","journal-title":"J Clin Invest"},{"issue":"9","key":"10298_CR34","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.hrthm.2009.05.021","volume":"6","author":"JD Kapplinger","year":"2009","unstructured":"Kapplinger JD, et al. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm. 2009;6(9):1297\u2013303.","journal-title":"Heart Rhythm"},{"issue":"17","key":"10298_CR35","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1093\/eurheartj\/ehab007","volume":"42","author":"M Gnecchi","year":"2021","unstructured":"Gnecchi M, Sala L, Schwartz PJ. Precision medicine and cardiac channelopathies: when dreams meet reality. Eur Heart J. 2021;42(17):1661\u201375.","journal-title":"Eur Heart J"},{"issue":"9","key":"10298_CR36","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1161\/CIRCULATIONAHA.105.549071","volume":"112","author":"L Crotti","year":"2005","unstructured":"Crotti L, et al. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation. 2005;112(9):1251\u20138.","journal-title":"Circulation"},{"issue":"2","key":"10298_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1161\/CIRCGENETICS.109.898569","volume":"3","author":"E Nof","year":"2010","unstructured":"Nof E, et al. A common single nucleotide polymorphism can exacerbate long-QT type 2 syndrome leading to sudden infant death. Circ Cardiovasc Genet. 2010;3(2):199\u2013206.","journal-title":"Circ Cardiovasc Genet"},{"key":"10298_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1471-2350-9-87","volume":"9","author":"X Zhang","year":"2008","unstructured":"Zhang X, et al. Protective effect of KCNH2 single nucleotide polymorphism K897T in LQTS families and identification of novel KCNQ1 and KCNH2 mutations. BMC Med Genet. 2008;9:87.","journal-title":"BMC Med Genet"},{"issue":"2","key":"10298_CR39","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00414-017-1739-7","volume":"132","author":"T Jenewein","year":"2018","unstructured":"Jenewein T, et al. Influence of genetic modifiers on sudden cardiac death cases. Int J Legal Med. 2018;132(2):379\u201385.","journal-title":"Int J Legal Med"},{"key":"10298_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.755642","volume":"12","author":"L van den Brink","year":"2021","unstructured":"van den Brink L, et al. The linkage phase of the polymorphism KCNH2-K897T influences the electrophysiological phenotype in hiPSC models of LQT2. Front Physiol. 2021;12: 755642.","journal-title":"Front Physiol"},{"issue":"1","key":"10298_CR41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1161\/CIRCGENETICS.111.960930","volume":"5","author":"S K\u00e4\u00e4b","year":"2012","unstructured":"K\u00e4\u00e4b S, et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet. 2012;5(1):91\u20139.","journal-title":"Circ Cardiovasc Genet"},{"issue":"3","key":"10298_CR42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1161\/CIRCGENETICS.114.000785","volume":"8","author":"I Kolder","year":"2015","unstructured":"Kolder I, et al. Analysis for genetic modifiers of disease severity in patients with long-QT syndrome type 2. Circ Cardiovasc Genet. 2015;8(3):447\u201356.","journal-title":"Circ Cardiovasc Genet"},{"issue":"9","key":"10298_CR43","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jacc.2009.06.005","volume":"54","author":"Y Nishio","year":"2009","unstructured":"Nishio Y, et al. D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome. J Am Coll Cardiol. 2009;54(9):812\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"10298_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2350-12-11","volume":"12","author":"AM Lahtinen","year":"2011","unstructured":"Lahtinen AM, et al. KCNE1 D85N polymorphism\u2013a sex-specific modifier in type 1 long QT syndrome? BMC Med Genet. 2011;12:11.","journal-title":"BMC Med Genet"},{"issue":"3","key":"10298_CR45","doi-asserted-by":"publisher","first-page":"e003234","DOI":"10.1161\/CIRCGEN.120.003234","volume":"14","author":"M Kim","year":"2021","unstructured":"Kim M, et al. Development of a patient-specific p.D85N-potassium voltage-gated channel subfamily E member 1-induced pluripotent stem cell-derived cardiomyocyte model for drug-induced long QT syndrome. Circ Genom Precis Med. 2021;14(3):e003234.","journal-title":"Circ Genom Precis Med"},{"issue":"17","key":"10298_CR46","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.109.879643","volume":"120","author":"L Crotti","year":"2009","unstructured":"Crotti L, et al. NOS1AP is a genetic modifier of the long-QT syndrome. Circulation. 2009;120(17):1657\u201363.","journal-title":"Circulation"},{"issue":"9","key":"10298_CR47","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jacc.2012.03.031","volume":"60","author":"Y Jamshidi","year":"2012","unstructured":"Jamshidi Y, et al. Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J Am Coll Cardiol. 2012;60(9):841\u201350.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10298_CR48","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.hrthm.2011.10.019","volume":"9","author":"S Saba","year":"2012","unstructured":"Saba S, et al. Cardiac levels of NOS1AP RNA from right ventricular tissue recovered during lead extraction. Heart Rhythm. 2012;9(3):399\u2013404.","journal-title":"Heart Rhythm"},{"issue":"11","key":"10298_CR49","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1073\/pnas.0709118105","volume":"105","author":"KC Chang","year":"2008","unstructured":"Chang KC, et al. CAPON modulates cardiac repolarization via neuronal nitric oxide synthase signaling in the heart. Proc Natl Acad Sci U S A. 2008;105(11):4477\u201382.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10298_CR50","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/CIRCULATIONAHA.108.821082","volume":"120","author":"DJ Milan","year":"2009","unstructured":"Milan DJ, et al. Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization. Circulation. 2009;120(7):553\u20139.","journal-title":"Circulation"},{"issue":"6","key":"10298_CR51","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.ajhg.2014.05.001","volume":"94","author":"A Kapoor","year":"2014","unstructured":"Kapoor A, et al. An enhancer polymorphism at the cardiomyocyte intercalated disc protein NOS1AP locus is a major regulator of the QT interval. Am J Hum Genet. 2014;94(6):854\u201369.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10298_CR52","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/cvr\/cvaa036","volume":"117","author":"C Ronchi","year":"2021","unstructured":"Ronchi C, et al. NOS1AP polymorphisms reduce NOS1 activity and interact with prolonged repolarization in arrhythmogenesis. Cardiovasc Res. 2021;117(2):472\u201383.","journal-title":"Cardiovasc Res"},{"issue":"49","key":"10298_CR53","doi-asserted-by":"publisher","first-page":"33730","DOI":"10.1074\/jbc.M114.592295","volume":"289","author":"K Roder","year":"2014","unstructured":"Roder K, et al. RING finger protein RNF207, a novel regulator of cardiac excitation. J Biol Chem. 2014;289(49):33730\u201340.","journal-title":"J Biol Chem"},{"issue":"10","key":"10298_CR54","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.hrthm.2014.06.030","volume":"11","author":"JR Priest","year":"2014","unstructured":"Priest JR, et al. Molecular diagnosis of long QT syndrome at 10 days of life by rapid whole genome sequencing. Heart Rhythm. 2014;11(10):1707\u201313.","journal-title":"Heart Rhythm"},{"issue":"2","key":"10298_CR55","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.hrthm.2021.10.005","volume":"19","author":"HA Ledford","year":"2022","unstructured":"Ledford HA, et al. Disruption of protein quality control of the human ether-\u00e0-go-go related gene K(+) channel results in profound long QT syndrome. Heart Rhythm. 2022;19(2):281\u201392.","journal-title":"Heart Rhythm"},{"issue":"24","key":"10298_CR56","doi-asserted-by":"publisher","first-page":"14469","DOI":"10.1073\/pnas.2437756100","volume":"100","author":"BS Finlin","year":"2003","unstructured":"Finlin BS, et al. Regulation of voltage-gated calcium channel activity by the Rem and Rad GTPases. Proc Natl Acad Sci U S A. 2003;100(24):14469\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10298_CR57","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.bbamem.2012.10.005","volume":"1828","author":"T Yang","year":"2013","unstructured":"Yang T, Colecraft HM. Regulation of voltage-dependent calcium channels by RGK proteins. Biochim Biophys Acta. 2013;1828(7):1644\u201354.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10298_CR58","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/35058574","volume":"2","author":"SA Goldstein","year":"2001","unstructured":"Goldstein SA, et al. Potassium leak channels and the KCNK family of two-P-domain subunits. Nat Rev Neurosci. 2001;2(3):175\u201384.","journal-title":"Nat Rev Neurosci"},{"issue":"8","key":"10298_CR59","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/bjp.2008.213","volume":"154","author":"J Gierten","year":"2008","unstructured":"Gierten J, et al. Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein. Br J Pharmacol. 2008;154(8):1680\u201390.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"10298_CR60","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrd.2015.34","volume":"15","author":"G Gintant","year":"2016","unstructured":"Gintant G, Sager PT, Stockbridge N. Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov. 2016;15(7):457\u201371.","journal-title":"Nat Rev Drug Discov"},{"key":"10298_CR61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.vascn.2016.06.002","volume":"81","author":"T Colatsky","year":"2016","unstructured":"Colatsky T, et al. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress. J Pharmacol Toxicol Methods. 2016;81:15\u201320.","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"5262","key":"10298_CR62","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1126\/science.272.5262.681","volume":"272","author":"MT Keating","year":"1996","unstructured":"Keating MT, Sanguinetti MC. Molecular genetic insights into cardiovascular disease. Science. 1996;272(5262):681\u20135.","journal-title":"Science"},{"issue":"22","key":"10298_CR63","doi-asserted-by":"publisher","first-page":"12329","DOI":"10.1073\/pnas.210244497","volume":"97","author":"JS Mitcheson","year":"2000","unstructured":"Mitcheson JS, et al. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A. 2000;97(22):12329\u201333.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10298_CR64","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1093\/eurheartj\/ehv695","volume":"37","author":"H Itoh","year":"2016","unstructured":"Itoh H, et al. The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J. 2016;37(18):1456\u201364.","journal-title":"Eur Heart J"},{"issue":"11 Suppl 1","key":"10298_CR65","first-page":"S3","volume":"128","author":"EG Navarrete","year":"2013","unstructured":"Navarrete EG, et al. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation. 2013;128(11 Suppl 1):S3-13.","journal-title":"Circulation"},{"issue":"1","key":"10298_CR66","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41467-017-01125-y","volume":"8","author":"M Kawatou","year":"2017","unstructured":"Kawatou M, et al. Modelling Torsade de Pointes arrhythmias in vitro in 3D human iPS cell-engineered heart tissue. Nat Commun. 2017;8(1):1078.","journal-title":"Nat Commun"},{"issue":"2","key":"10298_CR67","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/toxsci\/kfs309","volume":"131","author":"A Mehta","year":"2013","unstructured":"Mehta A, et al. Pharmacoelectrophysiology of viral-free induced pluripotent stem cell-derived human cardiomyocytes. Toxicol Sci. 2013;131(2):458\u201369.","journal-title":"Toxicol Sci"},{"key":"10298_CR68","doi-asserted-by":"crossref","unstructured":"Stillitano F, et al. Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells. Elife. 2017;6:e19406","DOI":"10.7554\/eLife.19406"},{"issue":"2","key":"10298_CR69","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.scr.2009.11.004","volume":"4","author":"SR Braam","year":"2010","unstructured":"Braam SR, et al. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 2010;4(2):107\u201316.","journal-title":"Stem Cell Res"},{"issue":"10","key":"10298_CR70","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1093\/europace\/eut272","volume":"15","author":"SG Priori","year":"2013","unstructured":"Priori SG, et al. Executive summary: HRS\/EHRA\/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace. 2013;15(10):1389\u2013406.","journal-title":"Europace"},{"issue":"1","key":"10298_CR71","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1161\/01.CIR.103.1.89","volume":"103","author":"PJ Schwartz","year":"2001","unstructured":"Schwartz PJ, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103(1):89\u201395.","journal-title":"Circulation"},{"issue":"11","key":"10298_CR72","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1001\/jama.292.11.1341","volume":"292","author":"SG Priori","year":"2004","unstructured":"Priori SG, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292(11):1341\u20134.","journal-title":"JAMA"},{"issue":"15","key":"10298_CR73","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1161\/01.CIR.0000125523.14403.1E","volume":"109","author":"PJ Schwartz","year":"2004","unstructured":"Schwartz PJ, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004;109(15):1826\u201333.","journal-title":"Circulation"},{"issue":"5","key":"10298_CR74","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jacc.2014.04.057","volume":"64","author":"Y Wang","year":"2014","unstructured":"Wang Y, et al. Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. J Am Coll Cardiol. 2014;64(5):451\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10298_CR75","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/eurheartj\/eht067","volume":"35","author":"E Matsa","year":"2014","unstructured":"Matsa E, et al. Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. Eur Heart J. 2014;35(16):1078\u201387.","journal-title":"Eur Heart J"},{"issue":"16","key":"10298_CR76","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/eurheartj\/ehx394","volume":"39","author":"A Mehta","year":"2018","unstructured":"Mehta A, et al. Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model. Eur Heart J. 2018;39(16):1446\u201355.","journal-title":"Eur Heart J"},{"issue":"5","key":"10298_CR77","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1161\/CIRCGEN.120.002950","volume":"13","author":"BJ O'Hare","year":"2020","unstructured":"O\u2019Hare BJ, et al. Promise and potential peril with lumacaftor for the trafficking defective type 2 long-QT syndrome-causative variants, p.G604S, p.N633S, and p.R685P, using patient-specific re-engineered cardiomyocytes. Circ Genom Precis Med. 2020;13(5):466\u201375.","journal-title":"Circ Genom Precis Med"},{"issue":"11","key":"10298_CR78","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1161\/01.RES.0000128561.28701.ea","volume":"94","author":"BP Delisle","year":"2004","unstructured":"Delisle BP, et al. Biology of cardiac arrhythmias: ion channel protein trafficking. Circ Res. 2004;94(11):1418\u201328.","journal-title":"Circ Res"},{"issue":"3","key":"10298_CR79","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1161\/CIRCULATIONAHA.105.570200","volume":"113","author":"CL Anderson","year":"2006","unstructured":"Anderson CL, et al. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation. 2006;113(3):365\u201373.","journal-title":"Circulation"},{"key":"10298_CR80","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.1038\/ncomms6535","volume":"5","author":"CL Anderson","year":"2014","unstructured":"Anderson CL, et al. Large-scale mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT syndrome. Nat Commun. 2014;5:5535.","journal-title":"Nat Commun"},{"issue":"7","key":"10298_CR81","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","volume":"2","author":"MP Boyle","year":"2014","unstructured":"Boyle MP, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014;2(7):527\u201338.","journal-title":"Lancet Respir Med"},{"issue":"23","key":"10298_CR82","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1093\/eurheartj\/ehz023","volume":"40","author":"PJ Schwartz","year":"2019","unstructured":"Schwartz PJ, et al. From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2. Eur Heart J. 2019;40(23):1832\u20136.","journal-title":"Eur Heart J"},{"issue":"16","key":"10298_CR83","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/eurheartj\/eht130","volume":"35","author":"D Sinnecker","year":"2014","unstructured":"Sinnecker D, Moretti A, Laugwitz KL. Negating the dominant-negative allele: a new treatment paradigm for arrhythmias explored in human induced pluripotent stem cell-derived cardiomyocytes. Eur Heart J. 2014;35(16):1019\u201321.","journal-title":"Eur Heart J"},{"issue":"23","key":"10298_CR84","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1089\/scd.2017.0172","volume":"26","author":"G Duncan","year":"2017","unstructured":"Duncan G, et al. Drug-mediated shortening of action potentials in LQTS2 human induced pluripotent stem cell-derived cardiomyocytes. Stem Cells Dev. 2017;26(23):1695\u2013705.","journal-title":"Stem Cells Dev"},{"issue":"9","key":"10298_CR85","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.15252\/emmm.201606260","volume":"8","author":"L Sala","year":"2016","unstructured":"Sala L, et al. A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells. EMBO Mol Med. 2016;8(9):1065\u201381.","journal-title":"EMBO Mol Med"},{"issue":"8","key":"10298_CR86","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1093\/cvr\/cvz247","volume":"116","author":"MD Perry","year":"2020","unstructured":"Perry MD, et al. Pharmacological activation of IKr in models of long QT Type 2 risks overcorrection of repolarization. Cardiovasc Res. 2020;116(8):1434\u201345.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10298_CR87","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4252\/wjsc.v11.i1.33","volume":"11","author":"P Machiraju","year":"2019","unstructured":"Machiraju P, Greenway SC. Current methods for the maturation of induced pluripotent stem cell-derived cardiomyocytes. World J Stem Cells. 2019;11(1):33\u201343.","journal-title":"World J Stem Cells"},{"issue":"6","key":"10298_CR88","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41569-019-0331-x","volume":"17","author":"E Karbassi","year":"2020","unstructured":"Karbassi E, et al. Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine. Nat Rev Cardiol. 2020;17(6):341\u201359.","journal-title":"Nat Rev Cardiol"},{"key":"10298_CR89","doi-asserted-by":"crossref","unstructured":"Veerman CC, et al. Switch from fetal to adult SCN5A isoform in human induced pluripotent stem cell-derived cardiomyocytes unmasks the cellular phenotype of a conduction disease-causing mutation. J Am Heart Assoc. 2017;6(7):e005135","DOI":"10.1161\/JAHA.116.005135"},{"issue":"12","key":"10298_CR90","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1161\/CIRCRESAHA.117.311920","volume":"121","author":"SS Parikh","year":"2017","unstructured":"Parikh SS, et al. Thyroid and glucocorticoid hormones promote functional T-tubule development in human-induced pluripotent stem cell-derived cardiomyocytes. Circ Res. 2017;121(12):1323\u201330.","journal-title":"Circ Res"},{"issue":"4","key":"10298_CR91","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.stemcr.2019.08.013","volume":"13","author":"X Yang","year":"2019","unstructured":"Yang X, et al. Fatty acids enhance the maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cell Reports. 2019;13(4):657\u201368.","journal-title":"Stem Cell Reports"},{"issue":"20","key":"10298_CR92","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1161\/CIRCULATIONAHA.114.014998","volume":"134","author":"JL Ruan","year":"2016","unstructured":"Ruan JL, et al. Mechanical stress conditioning and electrical stimulation promote contractility and force maturation of induced pluripotent stem cell-derived human cardiac tissue. Circulation. 2016;134(20):1557\u201367.","journal-title":"Circulation"},{"issue":"2","key":"10298_CR93","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.stem.2017.07.003","volume":"21","author":"JH Lee","year":"2017","unstructured":"Lee JH, et al. Human pluripotent stem cell-derived atrial and ventricular cardiomyocytes develop from distinct mesoderm populations. Cell Stem Cell. 2017;21(2):179-194.e4.","journal-title":"Cell Stem Cell"},{"issue":"9","key":"10298_CR94","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/nbt.3271","volume":"33","author":"MJ Birket","year":"2015","unstructured":"Birket MJ, et al. Expansion and patterning of cardiovascular progenitors derived from human pluripotent stem cells. Nat Biotechnol. 2015;33(9):970\u20139.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10298_CR95","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nbt.3745","volume":"35","author":"SI Protze","year":"2017","unstructured":"Protze SI, et al. Sinoatrial node cardiomyocytes derived from human pluripotent cells function as a biological pacemaker. Nat Biotechnol. 2017;35(1):56\u201368.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10298_CR96","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/j.stemcr.2018.04.006","volume":"10","author":"N Shaheen","year":"2018","unstructured":"Shaheen N, et al. Human induced pluripotent stem cell-derived cardiac cell sheets expressing genetically encoded voltage indicator for pharmacological and arrhythmia studies. Stem Cell Reports. 2018;10(6):1879\u201394.","journal-title":"Stem Cell Reports"},{"issue":"6","key":"10298_CR97","first-page":"1008","volume":"144","author":"E Giacomelli","year":"2017","unstructured":"Giacomelli E, et al. Three-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells. Development. 2017;144(6):1008\u201317.","journal-title":"Development"},{"issue":"6","key":"10298_CR98","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.stem.2020.05.004","volume":"26","author":"E Giacomelli","year":"2020","unstructured":"Giacomelli E, et al. Human-iPSC-derived cardiac stromal cells enhance maturation in 3D cardiac microtissues and reveal non-cardiomyocyte contributions to heart disease. Cell Stem Cell. 2020;26(6):862-879.e11.","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10298_CR99","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1096\/fj.13-228007","volume":"28","author":"IC Turnbull","year":"2014","unstructured":"Turnbull IC, et al. Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. Faseb j. 2014;28(2):644\u201354.","journal-title":"Faseb j"},{"issue":"8","key":"10298_CR100","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nmeth.2524","volume":"10","author":"SS Nunes","year":"2013","unstructured":"Nunes SS, et al. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat Methods. 2013;10(8):781\u20137.","journal-title":"Nat Methods"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-022-10298-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-022-10298-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-022-10298-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T22:11:57Z","timestamp":1677017517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-022-10298-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10298"],"URL":"https:\/\/doi.org\/10.1007\/s12265-022-10298-x","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"assertion":[{"value":"28 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}